

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau



30

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : A61K 49/04, 49/00		A2	(11) International Publication Number: WO 98/32469
			(43) International Publication Date: 30 July 1998 (30.07.98)
(21) International Application Number: PCT/GB98/00270			(74) Agents: GOLDING, Louise et al.; Frank B. Dehn & Co., 179 Queen Victoria Street, London EC4V 4EL (GB).
(22) International Filing Date: 29 January 1998 (29.01.98)			
(30) Priority Data: 9701813.9 29 January 1997 (29.01.97) GB 60/057,074 27 August 1997 (27.08.97) US			
(63) Related by Continuation (CON) or Continuation-in-Part (CIP) to Earlier Application US 60/057,074 (CIP) Filed on 27 August 1997 (27.08.97)			
(71) Applicant (for all designated States except US): NYCOMED IMAGING AS [NO/NO]; Nycoveien 1-2, N-0401 Oslo 4 (NO).			
(71) Applicant (for GB only): GOLDING, Louise [GB/GB]; Frank B. Dehn & Co., 179 Queen Victoria Street, London EC4V 4EL (GB).			
(72) Inventors; and (75) Inventors/Applicants (for US only): WOLFE, Henry [US/US]; Nycomed Inc., 466 Devon Park Drive, Wayne, PA			Published <i>Without international search report and to be republished upon receipt of that report.</i>
(54) Title: POLYMERS			
(57) Abstract The invention provides compounds comprising a linear, branched or dendrimeric polymer backbone with linked thereto at least one reporter moiety, said polymer backbone comprising a plurality of amine-containing acids. Such compounds may be linked to one or more targeting agents and are useful as therapeutic and diagnostic agents, in particular in medical imaging techniques.			

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

POLYMERS

The present invention relates to polymers useful as therapeutic and diagnostic agents and to processes for their preparation. In particular, the invention relates to amino acid based biodegradable polymers for use in targeting of diagnostic imaging and therapeutic agents.

The polymers in accordance with the invention are suitable for use in a variety of applications where specific delivery is desirable, and are particularly suited for the delivery of biologically active agents. However, a preferred use of the polymers of the invention is in the enhancement of images of selected mammalian organs, tissues and cells *in vivo* using MR, X-ray, ultrasound, light and nuclear imaging techniques by virtue of their enhanced imaging properties and site specificity. The polymers are especially suited for use as intravascular contrast agents and blood pool agents in such imaging techniques. As such they may be used in imaging blood vessels, e.g. in magnetic resonance angiography, in the measurement of blood flow and volume, in the identification and characterization of lesions by virtue of differences in vascularity from normal tissue, in the imaging of the lungs for the evaluation of pulmonary disease and in blood perfusion studies.

Medical imaging techniques, such as MRI and X-ray, have become extremely important tools in the diagnosis and treatment of disease. Some imaging of internal parts relies on inherent attributes of those parts, such as bones, to be differentiated from surrounding tissue in a particular type of imaging, such as X-ray. Other organs and anatomical components are only visible when specifically highlighted by particular imaging techniques.

One such technique with the potential to provide

images of a wide variety of anatomical components involves biotargeting image-enhancing metals. Such a procedure has the possibility of creating or enhancing images of specific organs and/or tumors or other such localized sites within the body, while reducing the background and potential interference created by simultaneous highlighting of non-desired sites.

It has been recognized for many years that chelating various metals increases the physiologically tolerable dosage of such metals and so permits their use *in vivo* to enhance images of body parts. One chelate complex which has been the subject of much study is Gd-DTPA. However, despite its satisfactory relaxivity and safety, this has several disadvantages. Due to its low molecular weight, Gd-DTPA is rapidly cleared from the blood stream. This severely limits the imaging window, the number of optimal images that can be taken after each injection, and increases the agent's required dose and relative toxicity. Moreover, such simple metal chelate image enhancers, without further modification, do not generally provide any significant site specificity.

The attachment of metal chelates to tissue or organ targeting molecules, e.g. biomolecules such as proteins, in order to produce site specific therapeutic or diagnostic agents has been widely suggested. Many such bifunctional chelating agents, i.e. agents which by virtue of the chelant moiety are capable of strongly binding a therapeutically or diagnostically useful metal ion and by virtue of the site-specific molecular component are capable of selective delivery of the chelated metal ion to the body site of interest, are known or have been proposed. However, drawbacks of conjugating metal chelates to protein carriers for use in MR imaging include inappropriate biodistribution, toxicity and short blood half-life. Their use in MR imaging is therefore limited. In addition, proteins

provide a defined structure not subject to wide synthetic variation.

Site-specific uses of various imaging techniques are enhanced by the use of a multiplicity of the appropriate metal ion conjugated to a site-directed macromolecule and numerous attempts have been made to produce bifunctional polychelants with increased numbers of chelant moieties per site-specific macromolecule.

For site-specific image enhancement however it is important that the site specificity of the tissue or organ targeting moiety of such chelates of bifunctional chelants should not be destroyed by the conjugation to the targeting moiety of the chelant moiety. Where the bifunctional chelant contains only one chelant moiety this is not generally a severe problem. However, when attempts have been made to produce bifunctional polychelants by conjugating several chelant moieties onto a single site-specific macromolecule, it has been found not only may the maximum achievable chelant:site-specific macromolecule ratio be relatively limited but as the ratio achieved increases, so the site-specificity of the resulting bifunctional polychelant decreases.

In order to overcome the problems of attaching larger numbers of chelant moieties to a site-specific macromolecule without destroying its site-specificity, i.e. without disturbing its binding site(s), there have been many proposals for the use of a backbone molecule to which large numbers of chelant moieties can be attached to produce a polychelant, one or more of which can then be conjugated to the site-specific macromolecule to produce the bifunctional polychelant.

Bifunctional polychelants in which the chelant moieties are residues of open chain PAPCAs, such as EDTA and DTPA, and in which the backbone molecule is a polyamine such as polylysine or polyethyleneimine have been produced.

WO-A-90/12050 describes techniques for producing

polychelants comprising macrocyclic chelating moieties, such as polylysine-polyDOTA, and for the preparation of corresponding bifunctional polychelants. This document also suggests the use of starburst dendrimers, such as a sixth generation PAMAM starburst dendrimer as the skeleton for such polychelants. WO-A-93/06868 similarly describes polychelants comprising dendrimeric backbone molecules linked to a plurality of macrocyclic chelant moieties, e.g. DOTA residues. These in turn may be conjugated to a site-directed molecule, e.g. a protein. However, to date starburst dendrimers have found little use in imaging.

Thus, there still exists a need for other polymeric contrast agents, e.g. MR, X-ray, ultrasound, light-based and nuclear, which contain relatively large amounts of metal per molecule, are of a molecular weight which enables them to be circulated within the blood for extended periods of time and which exhibit improved biodistribution.

The present invention lies in the recognition that co-polymers of amino acids carrying or attached to one or more reporter groups, e.g. chelating moieties, fluors, or absorbers, are particularly suitable for diagnostic and therapeutic use by virtue both of their structures and of their substantial uniformity in terms of molecular weight distribution. Moreover, by virtue of their relatively high molecular weights such compounds can function as effective blood pool agents without requiring attachment to site-directed biomolecules.

Thus viewed from one aspect the invention provides a compound comprising a linear, branched or dendrimeric polymer backbone with linked thereto at least one reporter moiety, said polymer backbone comprising a plurality of amine-containing acids, e.g. amino acid residues or similar non-native amine-containing acids; with the proviso that when the polymer backbone is

linear, the reporter moiety comprises an iodinated contrast agent, an ultrasound contrast agent, a light-based reporter or a metal chelator other than DOTA, DTPA or similar polyaminopolycarboxylic acids. When the polymer backbone is linear, the reporter moiety preferably comprises an iodinated contrast agent or TMT.


As used herein, the term "reporter moiety" is intended to define any atom, ion or molecule which may be linked to the polymer backbone to produce an effect which is detectable by any chemical, physical or biological examination. A reporter moiety may thus be either a therapeutic or diagnostic agent, e.g. a contrast agent or pharmacologic agent. Where two or more reporter moieties are attached to a given polymer backbone, these may be identical or different. Thus, these may comprise any combination of diagnostic and/or therapeutic agents. The number of attached reporter moieties depends on the structure of the polymer backbone, in particular the degree of any branching, but generally will be in the range of from 3 to 200, preferably up to 100, e.g. up to 50.

Dendrimeric (or cascade) polymers are preferred as the backbone moiety. These are formed from monomers which act as branching sites and with each successive branching a new "generation" is formed. The dendrimeric backbone molecule preferably comprises a multiplicity of native or non-native, preferably native amino acid residues arranged to extend radially outwards from a central core moiety. These amino acid residues may be terminally bonded directly, or optionally via a linking group, to one or more reporter groups. Alternatively, these may be terminally branched by the addition of further amino acid residues. A backbone molecule wherein a central branched core has itself been terminally branched once is termed a first-generation backbone molecule. Further terminal branching of the amino acid residues of first-generation backbone

molecules provides second, third, fourth etc. generation backbones. With each successive round of branching, the number of attachment points available for bonding to reporter groups increases. Depending on the nature of the central core moiety, branching from this may extend radially in one or more directions, resulting in either radially asymmetrical or symmetrical dendrimers. Preferably, the dendrimer backbone molecules are radially asymmetrical.

Dendrimeric polymers comprising a plurality of native or non-native, preferably native amino acid residues form a further aspect of the invention. Conveniently, these comprise from 3 to 200 amino acid residues, e.g. from 3 to 100 amino acid residues extending radially from a central core moiety.

Whilst the core moiety may itself comprise one or more amino acid residues, other core moieties are contemplated. Typically, the core moiety may be any molecule to which a multiplicity of successive amino acid residues may be attached and may itself comprise a reporter moiety. Suitable core moieties include $\text{H}_2\text{NCOCH}_2\text{CH}_2\text{CONH}_2$, and



in which $m=0-4$;

Y represents hydrogen or an alkyl or aryl group, e.g. a C_{1-6} alkyl group; and

X represents a $-\text{CO}_2\text{H}$, $-\text{SO}_2\text{Cl}$ or $-\text{CH}_2\text{Br}$ group, as well as modifications thereto and derivatives thereof.

In one embodiment of the invention, the dendrimer core may itself comprise a reporter moiety. Thus, in another aspect, the invention provides a compound comprising a dendrimeric polymer backbone extending


radially from a reporter moiety, said polymer backbone comprising a plurality of amino acid residues.

Preferably, biodegradable linking groups serve to link the reporter moieties to the polymer backbone. In this way, biodegradation of the compound at the targeted site results in release of the reporter moieties, e.g. an ionic or non-ionic contrast agent at the site of interest. Examples of suitable linking groups include amide, ether, thioether, guanidyl, acetal, ketal and phosphoester groups. Linkage between the backbone and the reporter groups is preferably via an amide bond, the amide nitrogen deriving from the backbone molecule and the amide carbonyl deriving from a carboxyl or carboxyl derivative on the reporter group.

The advantage of a biodegradable polymer is that it will not accumulate at the injection site, e.g. during lymphographic procedures, or in tissues, e.g. the liver during angiographic procedures provided its degradation rate is tuned to the required imaging time. Biodegradability of the compounds of the invention can be adjusted by selection of particular linker and peptide cluster compounds. Moreover, if desired, the biodegradability of the linkers and polymer backbones can be optimised *in vitro* using purified enzymes and/or biological fluids/tissues. The use of amino acid monomers which themselves are rapidly cleared may further aid clearance after imaging.

Preferred polymer backbones are those comprising from 3 to 200 amino acid residues, preferably from 3 to 100 amino acid residues and having a molecular weight of from 300 to 20,000 daltons. These are preferably bonded via peptide bonds, thereby ensuring the biodegradability of the polymer and subsequent elimination from the body. The polyamino acid may be a polymer of a single species or at least two different species of amino acids, or may be a block copolymer. Preferably the polyamino acid is poly-L-aspartic acid.

Particularly preferred compounds in accordance with the invention are those of formula I:



wherein n is an integer of from 1 to 100; and R represents a reporter group or a biodegradable linker-reporter adduct.

In a preferred embodiment of the invention, the reporter moieties are chelating agents. These are capable of chelating metal ions with a high level of stability, and may be metallated with the appropriate metal ion(s), e.g. to enhance images in MRI, gamma scintigraphy or X-ray or to deliver cytotoxic doses of radioactivity to kill undesirable cells such as tumors. Conveniently, the chelating agents are contrast agents comprising at least one paramagnetic metal ion. Alternatively, the chelating agents may be used in their unmetallated or undermetallated state for absorption of available metal ions *in vivo*, e.g. in metal detoxification.

The reporter moieties may also comprise therapeutic agents, e.g. antibiotic, analgesic, anti-inflammatory or other bioactive agents. Prolonged circulation in the blood of polymers carrying such agents substantially prolongs their therapeutic effect. Proteolysis of the

linking groups provides a release of therapeutic agent. Selection of a particular linking group thus provides the potential for a timed release of therapeutic agent at the desired site of interest.

If desired, the compounds in accordance with the invention can be attached by well-known methods to one or more site-directed molecules or targeting agents, e.g. a protein, to form bifunctional polymers which can enhance images and/or deliver cytotoxic doses of radioactivity to the targeted cells, tissues, organs, and/or body ducts. Targeting of contrast agents to the site of interest in this way increases the effectiveness of the imaging method. Such agents accumulate at the site of interest which is dependent upon the specificity of the targeting agent. Alternatively, the polymers may be used as blood pool agents without being coupled to site directed molecules.

For those compounds of the invention comprising a dendrimeric backbone moiety, any terminal amino acid residues may thus be bonded either directly or via a biodegradable linking group to either a reporter or a targeting agent. Preferably, where the core moiety is itself a reporter group, each terminal amino acid residue is bound via a biodegradable linking group to a targeting agent. In this way, a compound comprising more than one targeting agent can be provided. Conveniently the number of targeting agents will be from 1 to 128, preferably from 1 to 16, e.g. from 1 to 4.

In an alternative embodiment of the invention those compounds comprising a dendrimeric polymer backbone may comprise a targeting agent or site-directed macromolecule as the core moiety. The resulting peptide cluster may in turn be linked to one or more reporter moieties. Viewed from a yet further aspect, the invention thus provides a compound comprising a dendrimeric polymer backbone extending radially from a targeting agent, said polymer backbone comprising a

plurality of amino acid residues with linked thereto at least one reporter moiety.

The heat stable STa enterotoxin from E.coli as described in WO-A-95/11694 is particularly suitable as a core targeting agent. Attached Figure 1 illustrates a compound of the invention in which the STa peptide is linked to a poly-L-aspartic acid cluster (Asp₃) which in turn is linked to a plurality of TMT reporter molecules.

The polymers in accordance with the invention are in and of themselves useful entities in medical diagnosis and therapy, due in part to their unique localization in the body. The size of the polymer, typically 200 to 100,000 daltons, particularly 200 to 50,000 daltons, especially 10,000 to 40,000 daltons, radically alters its biodistribution. Selection of particular linking groups and/or variations in the polyamino acid sequence also affects the biodistribution of the polymers and the attached reporter or targeting agents.

The compounds of the invention generally have extended intravascular residence times, e.g. of the order of hours, although this can be specifically tailored according to the desired use of the compounds by selection of appropriate linking agents and/or modification of the polyamino acid sequence of the backbone polymer. Usually the compounds will eventually clear into the extracellular fluid (ECF) space and undergo renal excretion. Since the compounds remain primarily in the intravascular system for a diagnostically useful residence time, they are suitable for a range of uses from blood pool and cardiac perfusion imaging, CNS tumour detection and volume determination to thrombus detection and angiography. As blood pool agents they are particularly suited to use in studies of blood flow or volume, especially in relation to lesion detection and myocardial perfusion studies. The conventional monomeric MRI contrast agents which

rapidly disperse into the extracellular/extravascular space cannot readily be used for these purposes. Moreover in view of their enhanced relaxivity, the polymers according to the invention can be administered at significantly reduced dosages relative to current monomeric MRI contrast agents such as GdDTPA and GdDOTA, thus providing a significantly improved safety margin in their use.

The invention thus provides compounds which are able to provide MR contrast enhancement of the blood pool for long periods of time, which have a specificity towards accumulation in various body tissues, which provide relatively large amounts of metal and whose molecular weight can be synthetically tailored to produce an agent of desired composition, molecular weight and size.

Furthermore, by suitable selection of chelated species, chelates according to the invention may be produced which are capable of functioning as X-ray agents, e.g. by choosing tungsten, and also as MR contrast agents by choosing an appropriate metal ion e.g. a lanthanide ion.

Attachment of the compounds to a site-directed molecule results in even greater *in vivo* target specificity. The site-directed molecule is preferably an antibody, antibody fragment, other protein or other macromolecule which will travel *in vivo* to that site to deliver the chelated metals. In the present invention the capacity of this site-directed macromolecule to travel and/or bind to its target is not compromised by the addition of the chelated metals. The number of chelates per molecule is sufficient to enhance the image of that particular target.


Suitable chelating agents for attachment to the polymer backbone include both linear and macrocyclic PAPCAs. Examples of suitable PAPCAs include ethylenediamine tetraacetic acid (EDTA),

diethylenetriamine pentaacetic acid (DTPA), 1,4,7,10-tetraazacyclododecanetetraacetic acid (DOTA), 1,4,7,10-tetraazacyclododecane-1,4,7-triacetic acid (DO3A), 1-oxa-4,7,10-triazacyclododecanetriacetic acid (DOXA), 1,4,7-triazacyclononanetriacetic acid (NOTA) and 1,4,8,11-tetraazacyclotetradecanetetraacetic acid (TETA).

Other chelating agents suitable for attachment to the polymer backbone include terpyridines such as described in US-A-5367080, e.g. 4'-(3-amino-4-methoxyphenyl)-6,6"-bis(N',N'-dicarboxymethyl-N-methylhydrazino)-2,2':6',2"-terpyridine (THT) and 4'-(3-amino-4-methoxyphenyl)-6,6"-bis[N,N-di(carboxymethyl)aminomethyl]-2,2':6',2"-terpyridine (TMT).

Metals that can be incorporated, through chelation, include lanthanides and other metal ions, including isotopes and radioisotopes thereof, such as, for example, Mg, Ca, Sc, Ti, B, V, Cr, Mn, Fe, Co, Ni, Cu, Zn, Ga, Sr, Y, Zr, Tc, Ru, In, Hf, W, Re, Os, Pb and Bi. The choice of metal ion for chelation will depend upon the desired therapeutic or diagnostic application.

For use in X-ray contrast imaging, the reporter moiety may comprise an ionic or non-ionic iodinated monocyclic or bis-cyclic X-ray contrast agent. By mono and bis-cyclic is meant that the contrast agents contain either one or two iodinated rings. Generally, the iodinated rings will be di- or tri-iodinated, e.g. tri-iodinated aryl rings, in particular phenyl rings. Examples of iodinated contrast agents for use in accordance with the invention include iothexol, iopentol, iopamidol and iodixanol. Conveniently, one or more iodinated contrast agents may be conjugated to form an alternating co-polymer which in turn can be attached to the polymer backbone. An example of the synthesis of such a co-polymer from iodixanol is shown below:



The bifunctional agents in accordance with the invention involve coupling the compounds to a site-directed molecule. The site-directed molecules may be any of the molecules that naturally concentrate in a selected target organ, tissue, cell or group of cells, or other location in a mammalian body, *in vivo*. These

can include amino acids, oligopeptides (e.g. hexapeptides), molecular recognition units (MRU's), single chain antibodies (SCA's), proteins, non-peptide organic molecules, Fab fragments, and antibodies. Examples of site-directed molecules include polysaccharides (e.g. CCK and hexapeptides), proteins (such as lectins, asialofetuin, polyclonal IgG, blood clotting proteins (e.g. hirudin), lipoproteins and glycoproteins), hormones, growth factors, and clotting factors (such as PF4). Exemplary site-directed proteins include E.coli heat stable enterotoxin STa and its analogues, polymerized fibrin fragments (e.g., E₁), serum amyloid precursor (SAP) proteins, low density lipoprotein (LDL) precursors, serum albumin, surface proteins of intact red blood cells, receptor binding molecules such as estrogens, liver-specific proteins/polymers such as galactosyl-neoglycoalbumin (NGA) (see Vera et al. in Radiology 151: 191 (1984)) N-(2-hydroxy-propyl)methacrylamide (HMPA) copolymers with varying numbers of bound galactosamines (see Duncan et al., Biochim. Biophys. Acta 880:62 (1986)), and allyl and 6-aminohexyl glycosides (see Wong et al., Carbo. Res. 170:27 (1987)), and fibrinogen.

The site-directed protein can also be an antibody. The choice of antibody, particularly the antigen specificity of the antibody, will depend on the desired use of the conjugate. Monoclonal antibodies are preferred over polyclonal antibodies.

Human serum albumin (HSA) is a preferred protein for the study of the vascular system. HSA is available commercially from a number of sources including Sigma Chemical Co. Preparation of antibodies that react with a desired antigen is well known. Antibody preparations are available commercially from a variety of sources. Fibrin fragment E₁ can be prepared as described by Olexa et al. in J. Biol. Chem. 254:4925 (1979). Preparation of LDL precursors and SAP proteins is described by de

Beer et al. in J. Immunol. Methods 50:17 (1982). The above described articles are incorporated herein by reference in their entirety.

The compounds in accordance with the invention are conveniently prepared by conjugation of a linear, branched or dendrimeric backbone comprising a plurality of amino acid residues to one or more reporter groups in a non-reactive solvent. Linkage of the reporter groups to the backbone molecule may be effected through any reactive group and standard coupling techniques are known in the art. Preferred reaction conditions, e.g. temperature, solvents etc. depend primarily on the particular reactants and can be readily determined by those skilled in the art.

Methods for metallating any chelating agents present are within the level of skill in the art. Metals can be incorporated into a chelant moiety by any one of three general methods: direct incorporation, template synthesis and/or transmetallation. Direct incorporation is preferred.

Methods for attaching the polymer backbones to antibodies and other proteins are within the level of skill in the art. Such methods are described in Pierce 1989 Handbook and General Catalog and the references cited therein, Blatter et al, Biochem., 24:1517 (1985) and Jue et al, Biochem., 17:5399 (1978).

The polymer backbone itself may be synthesised in accordance with conventional peptide synthesis techniques. Suitable methods for forming the amino acid units are described in, for example, "Synthesis of Optically Active α -Amino Acids" by Robert M. Williams (Pergamon Press, 1989). In general, the reactive side chain groups present, e.g. amino, thiol and/or carboxy, will be protected during the coupling of the individual amino acids, although it is possible to leave some side chain groups unprotected, e.g. hydroxy, primary amide groups, during the entire synthetic procedure.

The final step in the synthesis of a compound in accordance with the invention will be the deprotection of a fully protected or partly protected derivative of such a compound and such a process forms part of the invention. Thus, the present invention provides a process for producing a compound as hereinbefore described, said process comprising deprotecting a partially or fully protected derivative thereof.

In building up the peptide chain, it is in principle possible to start either at the C-terminal or the N-terminal. However, only the C-terminal starting procedure is in common use. This is due to difficulties encountered when synthesising in the N to C direction which include an unacceptably high degree of racemisation (see Konig & Geiger, *Chemische Berichte* 103:2024-2033, 1970).

Contrary to expectation, it has been found that the peptide compounds for use in accordance with the invention may be produced in good yield and high purity (< 0.1% racemisation per step) by synthesising in the amino to carboxy direction. This method of synthesis has been found to be particularly effective in preparing the dendrimeric polymer backbones. In particular, these have been found to be more stable than those dendrimers derived from the more conventional Michael addition chemistry. Moreover, synthesising the polymer backbones in the amino to carboxy direction has been found to produce discrete polymers which are substantially non cross-linked and which have particularly low levels of racemic impurities.

Thus, in another aspect the invention further provides a process for the preparation of a compound comprising a linear, branched or dendrimeric polymer backbone with linked thereto at least one reporter moiety, said polymer backbone comprising a plurality of amino acid residues, said process comprising:

- (a) stepwise linking of successive protected amino acid residues in the amino to carboxy direction to form a polymer backbone;
- (b) linking the polymer backbone to one or more reporter moieties, optionally via a linking group; and
- (c) deprotecting any protected group.

Thus, one can start at the N-terminal by reaction of a suitably protected derivative of, for example, aspartic acid with a suitably protected derivative of a second aspartic acid molecule. The first aspartic acid derivative will have a protected amino group and a free carboxyl group while the other reactant will have either a free or activated α -amino group and a protected carboxyl group. After coupling, the intermediate may be purified, e.g. by chromatography, and then selectively deprotected to permit addition of further amino acid residues. This procedure is continued until the required amino acid sequence is completed.

A wide range of protecting groups for amino acids are known. Suitable amine protecting groups include carbobenzoxy (Z- or Cbz), t-butoxycarbonyl (Boc-) and 9-fluorenylmethoxycarbonyl (Fmoc-). Carboxyl protecting groups which may be used include benzyl (-Bzl) and t-butyl (-tBu).

A wide range of procedures exist for removing amine- and carboxyl-protecting groups. Amine protecting groups such as Boc and carboxyl protecting groups such as -tBu may be removed simultaneously by acid treatment, e.g. with trifluoroacetic acid.

The coupling of free amino and carboxyl groups may, for example, be effected using N,N'-dicyclohexyl carbodiimide (DCC). Other coupling agents which may be used include 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide (EDC) and 2-(1H-benzotriazolyl-1-yl)-

1,1,3-tetramethyluranium tetrafluoroborate (TBTU).

The coupling reactions may be effected at ambient temperatures, conveniently in a suitable solvent system, e.g. tetrahydrofuran, dimethylformamide, dimethylsulphoxide or a mixture of these solvents.

It may be convenient to carry out the peptide synthesis on a solid phase resin support. Amino acids are added stepwise to a growing peptide chain linked to an insoluble matrix, such as polystyrene beads. One advantage of this solid-phase method is that the desired product at each stage is bound to beads which can be rapidly filtered and washed so the need to purify intermediates is obviated. A number of suitable solid phase supports are known in the art, e.g. 4-hydroxy benzyl alcohol resin which has been modified to form an ester with succinic anhydride.

The compounds of the invention, especially the bifunctional polymers, may be administered to patients for imaging in amounts sufficient to yield the desired contrast with the particular imaging technique. Generally dosages of from 0.001 to 5.0 mmoles of chelated imaging metal ion per kilogram of patient bodyweight are effective to achieve adequate contrast enhancements. For most MRI applications preferred dosages of imaging metal ion will be in the range of -from 0.02 to 1.2 mmoles/kg bodyweight while for X-ray applications dosages of from 0.5 to 1.5 mmoles/kg are generally effective to achieve X-ray attenuation. Preferred dosages for most X-ray applications are from 0.8 to 1.2 mmoles of the lanthanide or heavy metal/kg bodyweight.

The dosage of the compounds of the invention for therapeutic use will depend upon the condition being treated, but in general will be of the order of from 1 pmol/kg to 1 mmol/kg bodyweight.

The compounds of the present invention may be formulated with conventional pharmaceutical or

veterinary aids, for example emulsifiers, fatty acid esters, gelling agents, stabilizers, antioxidants, osmolality adjusting agents, buffers, pH adjusting agents, etc., and may be in a form suitable for parenteral or enteral administration, for example injection or infusion or administration directly into a body cavity having an external escape duct, for example the gastrointestinal tract, the bladder or the uterus. Thus the compounds of the present invention may be in conventional pharmaceutical administration forms such as tablets, capsules, powders, solutions, suspensions, dispersions, syrups, suppositories etc. However, solutions, suspensions and dispersions in physiologically acceptable carrier media, for example water for injections, will generally be preferred.

The compounds according to the invention may therefore be formulated for administration using physiologically acceptable carriers or excipients in a manner fully within the skill of the art. For example, the compounds, optionally with the addition of pharmaceutically acceptable excipients, may be suspended or dissolved in an aqueous medium, with the resulting solution or suspension then being sterilized.

For MRI and for X-ray imaging of some portions of the body the most preferred mode for administering metal chelates as contrast agents is parenteral, e.g., intravenous administration. Parenterally administrable forms, e.g. intravenous solutions, should be sterile and free from physiologically unacceptable agents, and should have low osmolality to minimize irritation or other adverse effects upon administration, and thus the contrast medium should preferably be isotonic or slightly hypertonic. Suitable vehicles include aqueous vehicles customarily used for administering parenteral solutions such as Sodium Chloride Injection, Ringer's Injection, Dextrose Injection, Dextrose and Sodium Chloride Injection, Lactated Ringer's Injection and

other solutions such as are described in Remington's Pharmaceutical Sciences, 15th ed., Easton: Mack Publishing Co., pp. 1405-1412 and 1461-1487 (1975) and The National Formulary XIV, 14th ed. Washington: American Pharmaceutical Association (1975). The solutions can contain preservatives, antimicrobial agents, buffers and antioxidants conventionally used for parenteral solutions, excipients and other additives which are compatible with the chelates and which will not interfere with the manufacture, storage or use of products.

Viewed from a further aspect the invention provides a pharmaceutical composition, e.g. an image enhancing or therapeutic composition, comprising a compound of the invention together with at least one pharmaceutical carrier or excipient.

Viewed from a still further aspect the invention provides the use of a compound according to the invention or a chelate thereof for the manufacture of an image enhancing contrast medium or a therapeutic composition.

Viewed from another aspect the invention provides a method of generating an image of a human or non-human animal, especially mammalian, body which method comprises administering to said body an image enhancing amount of a compound according to the invention and thereafter generating an image e.g. an MR, X-ray, ultrasound or scintigraphic image, of at least a part of said body.

The present invention will now be further illustrated by way of the following non-limiting examples. Unless otherwise indicated, all percentages given are by weight.

!

Example 1: Asymmetric peptide cluster

Z- [Asp(α , γ -Asp₂(α , γ -Asp₄(α , γ -Asp₈(α , γ -Lys₁₆(α -Reporter₁₆)))]

(a) Bis- α , γ -(α , γ -(tButyl)-Aspartyl)-N-Cbz-Aspartamide
"Asp3 Cluster" (Compound I)

Into a 500 mL round bottom flask was added 8.5 mmoles N-Cbz-L-Aspartic acid, 10.2 mmoles N-hydroxybenzotriazole, 25 mL THF:DMF (2:1, v/v), and 10.2 mmoles EDC (1-ethyl-3-(3-dimethylaminopropyl)carbodiimide). After stirring at room temperature for 45 minutes, 20.4 mmoles of α , γ -(tButyl)-L-Aspartic acid and 25 mmoles of N,N'-diisopropylethylamine were added with stirring. After 4 hours, an additional 10.2 mmoles EDC was added and the reaction continued as above for 3 days. This slurry was worked up by aqueous extraction.

Purity: single spot on TLC, identity confirmed by MS and NMR. Yield: 44.5%.

(b) N-Cbz-Aspartamide-(α , γ -Aspartyl-(α , γ -(tButyl)-Aspartyl)) "Asp7 Cluster" (Compound II)

Into a 500 mL round bottom flask was added 10 mmoles Compound I, 95 mL chloroform:THF:acetonitrile (2.5:7:7), 36.4 mmoles N-hydroxybenzotriazole, and 36.5 mmoles DCC (N,N'-dicyclohexylcarbodiimide). After stirring at room temperature for 20 minutes, 40 mmoles of α , γ -(tButyl)-L-Aspartic acid was added and N,N'-diisopropylethylamine was added until the pH was approximately 7. After stirring at room temperature for 16 hours, the reaction was worked up by aqueous extraction.

Purity: single spot on TLC, identity confirmed by MS and NMR. Yield: 12.1%.

- 22 -

(c) N-Cbz-Aspartamide-((α,γ -Aspartyl-(α,γ -(tButyl)-Aspartyl)))) "Asp15 Cluster" (Compound III)

Step 1:

0.85 mmoles of Compound II was stirred in 200 mL of 95% trifluoroacetic acid (aq.) at room temperature for 8 hours. The reaction was evaporated to dryness at 40°C in vacuo and then re-evaporated to dryness from 200 mL of toluene and then from THF.

Step 2:

Into a 250 mL round bottom flask was added 0.85 mmoles from Step 1 above, 90 mL DMF:THF (1:1, v/v), 8.12 mmoles N-hydroxybenzotriazole, and 8.12 mmoles EDC (1-ethyl-3-(3-dimethylaminopropyl)carbodiimide). After stirring at room temperature for 20 minutes, 16.24 mmoles of α,γ -(tButyl)-L-Aspartic acid and 19.92 mmoles N,N'-diisopropylethylamine were added. After stirring at room temperature for 16 hours, the reaction was worked up by aqueous extraction and ion exchange chromatography.

Purity: single spot on TLC, identity confirmed by MS and NMR. Yield: 82.2%.

(d) N-Cbz-Aspartamide-((α,γ -Aspartyl-(α,γ -Aspartyl-(Aspartyl(α,γ -Lysyl((α -methoxyethylamide, e-amine)))))) "Asp15Lys16 Cluster" (Compound IV)

Step 1:

0.7 mmoles of Compound III was stirred in 200 mL of 95% trifluoroacetic acid (aq.) at room temperature for 8 hours. The reaction was evaporated to dryness at 40°C in vacuo and then re-evaporated to dryness from 200 mL

of toluene and then from THF.

Step 2:

Into a 250 mL round bottom flask was added 0.7 mmoles of compound from Step 1 above, 90 mL DMF:THF (1:1, v/v), 8.12 mmoles N-hydroxybenzotriazole, and 8.12 mmoles EDC (1-ethyl-3-(3-dimethylaminopropyl) carbodiimide). After stirring at room temperature for 20 minutes, 16.24 mmoles of α,γ -(tButyl)-L-Aspartic acid and 19.92 mmoles N,N'-diisopropylethylamine were added. After stirring at room temperature for 16 hours, the reaction was worked up by aqueous extraction and ion exchange chromatography.

Purity: single spot on TLC, identity confirmed by MS and NMR. Yield: 99%.

Step 3:

Into a 250 mL round bottom flask was added 0.7 mmoles of compound from Step 2 above, 100 mL DMSO:DMF:THF (1.5:3.5:5, v/v), 27.5 mmoles N-hydroxybenzotriazole, and 27.5 mmoles EDC (1-ethyl-3-(3-dimethylaminopropyl)carbodiimide). After stirring at room temperature for 20 minutes, 55 mmoles of α -BOC-L-Lysine and 68.7 mmoles N,N'-diisopropylethylamine were added. After stirring at room temperature for 16 hours, the reaction was worked up by aqueous extraction and Gel permeation chromatography.

Purity: single spot on TLC.

Step 4:

Into a 250 mL round bottom flask was added compound from Step 3 above, 40 mL DMF:DCM (2:2, v/v), 23.5 mmoles

N-hydroxybenzotriazole, and 23.5 mmoles EDC (1-ethyl-3-(3-dimethylaminopropyl)carbodiimide). After stirring at room temperature for 30 minutes, 75 mmoles of 2-methoxyethanolamine were added. After stirring at room temperature overnight, the reaction was worked up by aqueous extraction and Ion Exchange chromatography.

Purity: single spot on TLC. Yield: 90%.

(e) N-Cbz-Aspartamide-((α,γ -Aspartyl-(α,γ -Aspartyl-(Aspartyl(α,γ -Lysyl((α -methoxyethylamide, ϵ -TMT)))))) "Asp15Lys16TMT16 Cluster" (Compound V)

Into a 250 mL round bottom flask was added Compound IV, 1.1 molar equivalents of TMT-NCS and 100 mL of 50 mM sodium borate at pH 9.0. After stirring at room temperature for 48 hours, the reaction was worked up by diafiltration (2000 MW cutoff).

Purity: 80% by RP-HPLC.

Example 2: Symmetric aspartic acid cluster

(a) Bis-(α,γ -(tButyl)-Aspartyl)succinamide (Compound I)

Synthetic Route A:

Into a 2 Litre round bottom flask was added 20 mmoles succinic acid, 26 mmoles EDC (1-ethyl-3-(3-dimethylaminopropyl)carbodiimide), 24 mmoles triethylamine, 12 mmoles TBTU (2-(1-H-benzotriazolyl-1-yl)-1,1,3,3-tetramethyluronium tetrafluoroborate), and 150 mL THF:DMF (2:1, v/v), then 20 mmoles α,γ -(tButyl)-L-Aspartic acid. This slurry was allowed to react for 4 days at room temperature and then worked up by aqueous extraction.

Purity: single spot on TLC, identity confirmed by MS and NMR. Yield: 23.2%.

Synthetic Route B:

Into a 2 Litre round bottom flask was added 10 mmoles succinic acid, 100 mL THF:DMF (2:1 v/v), 60 mmoles triethylamine and 20 mmoles TBTU (2-(1-H-benzotriazol-1-yl)-1,1,3,3-tetramethyluronium tetrafluoroborate). After 15 minutes of stirring, 22 mmoles α,γ -(tButyl)-L-Aspartic acid were added. This slurry was allowed to react for 21 hours at room temperature and then worked up by aqueous extraction.

Purity: single spot on TLC, identity confirmed by MS and NMR. Yield: 64.7%.

(b) (Bis- α,γ -Aspartyl-(α,γ -(tButyl)-Aspartyl))-succinamide (Compound II)

Step 1:

4.6 mmoles of Compound I was stirred into 100 mL of trifluoroacetic acid/dichloromethane (1:1, v/v) at room temperature for 45 minutes. The reaction was evaporated to dryness at 30°C in vacuo and then re-evaporated to dryness from each of five consecutive 100 mL volumes of chloroform.

Step 2:


The product from Step 1 was dissolved in 250 mL THF:DMF (1:1, v/v) with 60 mmoles of triethylamine and 40 mmoles of L-aspartic acid-(α,γ -(tButyl)ester). To this solution was added 60 mmoles of TBTU. After 16 hours, an additional 20 mmoles of L-aspartic acid-(α,γ -(tButyl)ester) was added and the reaction continued

overnight.

Aqueous workup and ion-exchange chromatography yielded a single major spot on TLC which was identified as the desired compound by MS and NMR. Yield: 90%.

Example 3: X-ray contrast agent


(a) Synthesis of iodinated monomer (Compound I):



(b) Compound I may be coupled to any one of the Asp_x clusters described in Examples 1 and 2 to form an iodinated X-ray contrast agent.

Claims:

1. A compound comprising a linear, branched or dendrimeric polymer backbone with linked thereto at least one reporter moiety, said polymer backbone comprising a plurality of amine-containing acids; with the proviso that when the polymer backbone is linear, at least one reporter moiety comprises an iodinated contrast agent, an ultrasound contrast agent, a light-based reporter or a metal chelator other than a DOTA or DTPA-based polyaminocarboxylic acid.
2. A compound as claimed in claim 1, wherein said polymer backbone comprises a plurality of native or non-native amino acid residues.
3. A compound as claimed in claim 2, wherein said polymer backbone comprises from 3 to 200 amino acid residues.
4. A compound as claimed in any one of claims 1 to 3, wherein said polymer backbone comprises a dendrimer.
5. A compound as claimed in claim 4, wherein said dendrimer comprises from 3 to 200 amino acid residues extending radially from a central core moiety.
6. A compound as claimed in claim 5, wherein said core moiety is selected from $\text{H}_2\text{NCOCH}_2\text{CH}_2\text{CONH}_2$, and



(wherein $m=0-4$;

each Y independently represents hydrogen or an

alkyl or aryl group; and

each X independently represents a -CO₂H, -SO₂Cl or -CH₂Br group) and derivatives thereof.

7. A compound as claimed in claim 5, wherein said core moiety comprises a reporter moiety.

8. A compound as claimed in claim 5, wherein said core moiety comprises a targeting agent capable of travelling to or binding specifically to targeted cells, tissues, organs or other locations in a mammalian body.

9. A compound as claimed in any one of claims 4 to 8, wherein said dendrimer is radially asymmetrical.

10. A compound as claimed in any preceding claim, wherein said polymer backbone has a molecular weight of from 300 to 20,000 daltons.

11. A compound as claimed in any one of claims 2 to 10, wherein said polymer backbone comprises a polymer of a single species or at least two different species of amino acids, or a block copolymer.

12. A compound as claimed in claim 11, wherein said polymer backbone is poly-L-aspartic acid.


13. A compound as claimed in any preceding claim comprising from 3 to 200 reporter moieties.

14. A compound as claimed in any preceding claim, wherein each reporter moiety is linked to said polymer backbone via a biodegradable linking group.

15. A compound as claimed in claim 14, wherein said linking group is selected from amide, ether, thioether, guanidyl, acetal, ketal and phosphoester groups.

16. A compound as claimed in claim 14, wherein said linking group comprises an amide bond, the amide nitrogen deriving from the backbone molecule and the amide carbonyl deriving from a carboxyl or carboxyl derivative on the reporter group.

17. A compound as claimed in claim 1 of formula I:



(wherein n is an integer of from 1 to 100; and R represents a reporter moiety, optionally linked to the polymer backbone via a biodegradable linking group).

18. A compound as claimed in any preceding claim, wherein at least one reporter moiety comprises a diagnostic or therapeutic agent.

19. A compound as claimed in claim 18, wherein said agent comprises the residue of a chelating agent or metal chelate thereof.

20. A compound as claimed in claim 19, wherein said chelating agent is a contrast agent comprising at least one paramagnetic metal ion.

21. A compound as claimed in claim 20, wherein said metal ion is selected from the lanthanide metal ions, Mg, Ca, Sc, Ti, B, V, Cr, Mn, Fe, Co, Ni, Cu, Zn, Ga, Sr, Y, Zr, Tc, Ru, In, Hf, W, Re, Os, Pb and Bi.
22. A compound as claimed in claim 19 or claim 20, wherein said chelating agent is selected from ethylenediamine tetraacetic acid (EDTA), diethylenetriamine pentaacetic acid (DTPA), 1,4,7,10-tetraazacyclododecanetetraacetic acid (DOTA), 1,4,7,10-tetraazacyclododecane-1,4,7-triacetic acid (DO3A), 1-oxa-4,7,10-triazacyclododecanetriacetic acid (DOXA), 1,4,7-triazacyclononanetriacetic acid (NOTA) and 1,4,8,11-tetraazacyclotetradecanetetraacetic acid (TETA).
23. A compound as claimed in claim 19 or claim 20, wherein said chelating agent is selected from 4'-(3-amino-4-methoxy-phenyl)-6,6"-bis(N',N'-dicarboxymethyl-N-methylhydrazino)-2,2':6',2"-terpyridine (THT) and 4'-(3-amino-4-methoxy-phenyl)-6,6"-bis[N,N-di(carboxymethyl)aminomethyl]-2,2':6',2"-terpyridine (TMT).
24. A compound as claimed in claim 18, wherein said agent comprises an ionic or non-ionic iodinated monocyclic or bis-cyclic X-ray contrast agent.
25. A compound as claimed in any preceding claim linked to a targeting agent capable of travelling to or binding specifically to targeted cells, tissues, organs or other locations in a mammalian body.
26. A compound as claimed in claim 8 or claim 25, wherein said targeting agent comprises *E. coli* heat stable enterotoxin STa or an analogue thereof.

27. A dendrimeric polymer comprising a plurality of native or non-native amino acid residues extending radially from a central core moiety.

28. A dendrimeric polymer as claimed in claim 27, wherein said core moiety is as defined in any one of claims 6 to 8.

29. A process for preparing a compound as claimed in any one of claims 1 to 26, said process comprising conjugating at least one reporter moiety to a linear, branched or dendrimeric polymer backbone comprising a plurality of amino acid residues.

30. A process for preparing a compound as claimed in any one of claims 1 to 26, said process comprising the step of deprotecting a partially or fully protected derivative thereof.

31. A process for the preparation of a compound comprising a linear, branched or dendrimeric polymer backbone with linked thereto at least one reporter moiety, said polymer backbone comprising a plurality of amino acid residues, said process comprising:

(a) stepwise linking of successive protected amino acid residues in the amino to carboxy direction whereby to form a polymer backbone;

(b) linking the polymer backbone to one or more reporter moieties, optionally via a linking group; and

(c) deprotecting any protected group.

32. A pharmaceutical composition comprising a compound as claimed in any one of claims 1 to 26, together with


at least one pharmaceutical carrier or excipient. .

33. Use of a compound as claimed in any one of claims 1 to 26 in the manufacture of an image enhancing contrast medium or a therapeutic composition.

34. A method of generating an image of the human or non-human animal body, said method comprising the step of administering to said body a compound as claimed in any one of claims 1 to 26 and thereafter generating an image of at least a part of said body.


1/2

Fig. 1A



SUBSTITUTE SHEET (RULE 26)

Fig. 1B



PCTWORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : A61K 49/04, 49/00, C07K 5/02, 7/02, 14/00, 1/04 // C07K 14/245	A3	(11) International Publication Number: WO 98/32469 (43) International Publication Date: 30 July 1998 (30.07.98)
(21) International Application Number: PCT/GB98/00270 (22) International Filing Date: 29 January 1998 (29.01.98) (30) Priority Data: 9701813.9 29 January 1997 (29.01.97) GB 60/057,074 27 August 1997 (27.08.97) US (63) Related by Continuation (CON) or Continuation-in-Part (CIP) to Earlier Application US 60/057,074 (CIP) Filed on 27 August 1997 (27.08.97) (71) Applicant (for all designated States except US): NYCOMED IMAGING AS [NO/NO]; Nycoveien 1-2, N-0401 Oslo 4 (NO). (71) Applicant (for GB only): GOLDING, Louise [GB/GB]; Frank B. Dehn & Co., 179 Queen Victoria Street, London EC4V 4EL (GB). (72) Inventors; and (75) Inventors/Applicants (for US only): WOLFE, Henry [US/US]; Nycomed Inc., 466 Devon Park Drive, Wayne, PA		(74) Agents: GOLDING, Louise et al.; Frank B. Dehn & Co., 179 Queen Victoria Street, London EC4V 4EL (GB). (81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, GW, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG). Published <i>With international search report.</i> (88) Date of publication of the international search report: 5 November 1998 (05.11.98)
(54) Title: POLYMERS (57) Abstract The invention provides compounds comprising a linear, branched or dendrimeric polymer backbone with linked thereto at least one reporter moiety, said polymer backbone comprising a plurality of amine-containing acids. Such compounds may be linked to one or more targeting agents and are useful as therapeutic and diagnostic agents, in particular in medical imaging techniques.		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

INTERNATIONAL SEARCH REPORT

International Application No

PCT/GB 98/00270

A. CLASSIFICATION OF SUBJECT MATTER

IPC 6 A61K49/04 A61K49/00 C07K5/02 C07K7/02 C07K14/00
C07K1/04 //C07K14/245

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 6 A61K C07K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 93 10824 A (GUERBET SA) 10 June 1993 see abstract see page 6 - page 7; claims 2-6,12,13; examples 4,6	1-5,7, 9-16,18, 24, 27-30, 32-34
X	EP 0 331 616 A (SCHERING AG) 6 September 1989 see page 7, line 20-23; examples 60,61	1-5, 7-23,25, 29-34

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents:

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

"&" document member of the same patent family

Date of the actual completion of the international search

16 July 1998

Date of mailing of the international search report

31.07.98

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Gonzalez Ramon, N

INTERNATIONAL SEARCH REPORT

International Application No

PCT/GB 98/00270

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 96 40816 A (SCHERING AG ;KRAUSE WERNER (DE); MAIER FRANZ (DE); BAUER MICHAEL ()) 19 December 1996 see page 15, line 20-26 see page 23, line 1-5; claims 1,5,7	1-3, 10-18, 24-30, 32-34
X	WO 96 40760 A (SCHERING AG) 19 December 1996 see page 21; claims 1,2,15	1-7, 9-18, 24-30, 32-34
X	WO 93 06868 A (COCKBAIN JILIAN RODERICK MICHA ;NYCOMED SALUTAR INC (US)) 15 April 1993	1-5, 7-23,25, 27-30, 32-34
Y	see abstract; claims 1-10,14-16,19-21; examples 9-12,17,18	8,25,26
X	EP 0 481 526 A (SALUTAR INC) 22 April 1992	1-5, 7-23,25, 27-30, 32-34
Y	see abstract see page 5, line 40-47 see page 9, line 20-30; claims 1-9; examples 12,17,18,27	8,25,26
X	WO 94 05203 A (GEN HOSPITAL CORP) 17 March 1994	1-23, 27-34
Y	see page 8 - page 9 see page 16, line 20-26 see page 22, line 10-20; claims 10,11,16,17,21-24 see claims 32-34,36	1-6, 10-12
Y	RANGANATHAN, DARSHAN ET AL: "Synthesis of totally chiral, multiple armed, poly Glu and poly Asp scaffoldings on bifunctional adamantane core" TETRAHEDRON LETT., 1997, 38, 1265-1268, XP004034251 see page 1265; figure 2	1-6, 10-12
Y	WO 85 02611 A (SCRIPPS CLINIC RES) 20 June 1985 see abstract	8,25,26

INTERNATIONAL SEARCH REPORT

international application No.

PCT/GB 98/ 00270

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.: 32-34
because they relate to subject matter not required to be searched by this Authority, namely:
Remark: Although claim(s) 32-34
is(are) directed to a method of treatment of the human/animal
body, the search has been carried out and based on the alleged
effects of the compound/composition.
2. ☐ Claims Nos.:
because they relate to parts of the International Application that do not comply with the prescribed requirements to such
an extent that no meaningful International Search can be carried out, specifically:
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all
searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment
of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report
covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is
restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/GB 98/00270

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
WO 9310824	A	10-06-1993	FR 2684678 A	11-06-1993
			FR 2688508 A	17-09-1993
			AU 3354993 A	28-06-1993
			CA 2125188 A	10-06-1993
			EP 0616538 A	28-09-1994
			JP 7506085 T	06-07-1995
EP 0331616	A	06-09-1989	DE 3806795 A	07-09-1989
			AT 130017 T	15-11-1995
			DE 58909479 D	21-12-1995
			GR 3018071 T	29-02-1996
			JP 2196864 A	03-08-1990
			JP 2685568 B	03-12-1997
			NO 174394 B	17-01-1994
			US 5681543 A	28-10-1997
			US 5681544 A	28-10-1997
WO 9640816	A	19-12-1996	DE 19521940 A	12-12-1996
WO 9640760	A	19-12-1996	US 5756066 A	26-05-1998
			EP 0835259 A	15-04-1998
WO 9306868	A	15-04-1993	AU 671601 B	05-09-1996
			AU 2675792 A	03-05-1993
			CA 2120763 A	15-04-1993
			EP 0607222 A	27-07-1994
			JP 7503031 T	30-03-1995
EP 0481526	A	22-04-1992	US 5364613 A	15-11-1994
			AT 139790 T	15-07-1996
			AT 150047 T	15-03-1997
			AU 656304 B	02-02-1995
			AU 5423590 A	05-11-1990
			CA 2051648 A	08-10-1990
			DE 69027603 D	01-08-1996
			DE 69027603 T	05-12-1996
			DE 69030186 D	17-04-1997
			DE 69030186 T	19-06-1997
			WO 9012050 A	18-10-1990
			EP 0474642 A	18-03-1992

INTERNATIONAL SEARCH REPORT

information on patent family members

International Application No

PCT/GB 98/00270

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
EP 0481526 A		ES 2088428 T	16-08-1996
		ES 2098299 T	01-05-1997
		IE 74852 B	13-08-1997
		JP 4504436 T	06-08-1992
		NO 178866 B	11-03-1996
		US 5554748 A	10-09-1996
WO 9405203 A	17-03-1994	AU 5085793 A	29-03-1994
		EP 0665729 A	09-08-1995
		JP 8501097 T	06-02-1996
		US 5593658 A	14-01-1997
WO 8502611 A	20-06-1985	US 4603049 A	29-07-1986
		AU 572821 B	19-05-1988
		AU 2436884 A	02-08-1984
		AU 3747185 A	26-06-1985
		DK 364685 A	09-08-1985
		DK 421584 A	03-09-1984
		EP 0117367 A	05-09-1984
		EP 0165307 A	27-12-1985
		FI 843451 A	03-09-1984
		FI 853082 A	12-08-1985
		JP 61500664 T	10-04-1986
		PT 77910 B	11-04-1986
		US 4758655 A	19-07-1988
		WO 8402700 A	19-07-1984
		US 4886663 A	12-12-1989

THIS PAGE BLANK (USPTO)